Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för elisidepsin. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

7 träffar

Bibliografisk träff 2014-01-07

Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.

Goldwasser F, Faivre S, Alexandre J, Coronado C, Fernández-García EM, Kahatt CM, Paramio PG, Dios JL, Miguel-Lillo B, Raymond E.

Invest New Drugs · multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s10637-013-0060-7

Bibliografisk träff 2013-12-02

Hypoxia reduces the efficiency of elisidepsin by inhibiting hydroxylation and altering the structure of lipid rafts.

Király A, Váradi T, Hajdu T, Rühl R, Galmarini CM, Szöllősi J, Nagy P.

Mar Drugs · research support, non-u.s. gov't; research-article; journal article · DOI 10.3390/md11124858

Bibliografisk träff 2013-03-20

Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound.

Serova M, de Gramont A, Bieche I, Riveiro ME, Galmarini CM, Aracil M, Jimeno J, Faivre S, Raymond E.

Mar Drugs · research support, non-u.s. gov't; research-article; journal article · DOI 10.3390/md11030944

Tillbakadragen publikation 2013-01-08

Epithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell lines.

Teixidó C, Marés R, Aracil M, Ramón y Cajal S, Hernández-Losa J.

PLoS One · retracted publication; research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0053645

Bibliografisk träff 2012-08-25

A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors.

Salazar R, Jones RJ, Oaknin A, Crawford D, Cuadra C, Hopkins C, Gil M, Coronado C, Soto-Matos A, Cullell-Young M, Iglesias Dios JL, Evans TR.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s00280-012-1951-6

Bibliografisk träff 2012-04-03

ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.

Teixidó C, Arguelaguet E, Pons B, Aracil M, Jimeno J, Somoza R, Marés R, Ramón Y Cajal S, Hernández-Losa J.

Int J Oncol · research support, non-u.s. gov't; journal article · DOI 10.3892/ijo.2012.1425

Bibliografisk träff 2011-06-02

ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment.

Váradi T, Roszik J, Lisboa D, Vereb G, Molina-Guijarro JM, Galmarini CM, Szöllosi J, Nagy P.

Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2011.05.064